A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

This study is testing a combination treatment for men with prostate cancer that has spread to other parts of the body (metastatic prostate cancer). It is evaluating a new drug called HRS-1167 used together with abiraterone acetate and prednisone — a standard hormone-blocking combination — to see if adding HRS-1167 improves outcomes. **You may be eligible if...** - You are male, 18 or older - You have been diagnosed with metastatic prostate cancer confirmed by biopsy - Your cancer has been confirmed to have spread (seen on scans) - You have a good general health status (ECOG 0–1) - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have received prior systemic treatment for prostate cancer in certain contexts (eligibility depends on the specific study stage) - You have significant heart, liver, or kidney problems - You are unwilling to use contraception if your partner could become pregnant Talk to your doctor to see if this trial is right for you.